Ardelyx (NASDAQ:ARDX) Rating Reiterated by Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report released on Friday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the biopharmaceutical company’s stock. A number of other research analysts also recently weighed in on ARDX. Citigroup increased their price target on Ardelyx […]

Leave a Reply

Your email address will not be published.

Previous post Affirm (NASDAQ:AFRM) Receives “Sector Perform” Rating from Royal Bank of Canada
Next post Airbus to Hire 400 British Engineers Amid Boeing’s Struggles